about
sameAs
Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment StrategyDuration of untreated psychosis and negative symptoms--a systematic review and meta-analysis of individual patient data.Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T 1H-MRS Study.A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial.Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial.E-mental health self-management for psychotic disorders: state of the art and future perspectives.Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medicationCognitive alexithymia is associated with the degree of risk for psychosis.Social Cognition in Individuals at Ultra-High Risk for Psychosis: A Meta-Analysis.Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial.Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.Assertive community treatment in the Netherlands: a randomized controlled trial.The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population.Clinical recovery in first-episode psychosisA web-based tool to support shared decision making for people with a psychotic disorder: randomized controlled trial and process evaluation.A manual-based individual therapy to improve metacognition in schizophrenia: protocol of a multi-center RCT.Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.The effect of childhood adversity on 4-year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial.The Prodromal Questionnaire: a case for IRT-based adaptive testing of psychotic experiences?Ethnicity and baseline symptomatology in patients with an At Risk Mental State for psychosis.Development of a stage-dependent prognostic model to predict psychosis in ultra-high-risk patients seeking treatment for co-morbid psychiatric disorders.Association of treatment delay, migration and urbanicity in psychosis.Four-Year Cost-effectiveness of Cognitive Behavior Therapy for Preventing First-episode Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial.Lower prefrontal activation during emotion regulation in subjects at ultrahigh risk for psychosis: an fMRI-study.Taking a Bleulerian perspective: a role for negative symptoms in the staging model?Detection of psychosis by mental health care services; a naturalistic cohort study.Who needs antipsychotic maintenance treatment and who does not? Our need to profile and personalize the treatment of first episode psychosis.Citalopram Discontinuation More Harmful Than Gradual Dosage Reduction?Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: a randomized controlled trial.Depression and social anxiety in help-seeking patients with an ultra-high risk for developing psychosis.COMT Val(158)Met genotype and cannabis use in people with an At Risk Mental State for psychosis: Exploring Gene x Environment interactions.Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial.Adding evidence-based interventions to assertive community treatment: a feasibility study.Early medication discontinuation on long-term recovery outcome in first-episode psychosis--reply.Neurocognition and recovery in first episode psychosis.Improving detection of first-episode psychosis by mental health-care services using a self-report questionnaire.Treatment delay and response rate in first episode psychosis.A Smart Screening Device for Patients with Mental Health Problems in Primary Health Care: Development and Pilot Study.A Smart Screening Device for Patients with Mental Health Problems in Primary Health Care: Development and Pilot Study (Preprint)Practical Implications of Metacognitively Oriented Psychotherapy in Psychosis
P50
Q23009758-6f0a3ee1-4f79-c003-d9c9-5663fad90e34Q30571553-C527E3FD-5264-420C-9450-D4D4A65B01FCQ31048306-EF596D75-F324-43B3-BC3B-5BA5BDFBAE12Q33784930-507EDE22-E2DE-4E8B-9E33-2ADB3629B765Q34186391-15C73F87-2733-4B6C-A025-8FB518ECDC0EQ35017902-BA17AF44-4DEC-4249-A455-77F6D56F4ECAQ35064650-98BAC230-2357-4EB3-B8C1-0D3E1B335FB0Q35647896-0796C4F7-BF84-4177-A6DB-636B85DC850EQ35824639-93CF9477-674C-45BB-8FE6-2C9121B6B7A8Q36386323-3D8308D2-0C64-4D31-ACE9-87CF521E82BFQ36853291-FDCB9D35-E4D2-4B15-B806-D4E518688012Q36890666-2E43D155-473C-4506-A3DB-AB25CA863938Q37018067-35CD00E0-A2DC-4310-9F35-8771763B3168Q37137014-5D089F12-26BB-46E2-B63F-7EDA30223122Q37250963-21DB1EA6-1255-4D96-A03C-65154341A912Q37579662-AC1C6FFF-B9CA-4131-87DD-845EC31BC0FDQ38815384-C4016BE4-F41E-4509-B92B-1CA4EB8C9700Q39174161-EEF5D61C-63D7-40CF-97E6-C5AEEA357141Q39549418-3E0F9E22-6A1C-4B0B-B43B-4B9B20A650F5Q39556500-0E1A03FB-E74F-4490-B079-102E6951B163Q39919011-7C34D6E9-8171-4FE2-B420-11F076CF1BE4Q39988578-A3142D02-E10C-4870-9DE1-49920FD19305Q40699542-79AABC94-0732-48AF-9599-A887033FFD77Q40765487-0CDB5A19-209B-409D-A72E-31AB6A217ECFQ41658764-857FEA7F-ABA5-461A-8D03-2C59B18F42E3Q42086895-2C98B9B4-D65A-4961-89B7-6BDA0AADF75BQ47575403-8ABECC09-A141-419E-AFF5-4801C214D8D7Q47736303-03658970-2C7C-40D2-BE6D-A281FFDF16D0Q48486145-5430F906-8F88-4921-830C-BC626492CE2EQ48512127-4580928A-231C-4E76-9DFB-6BA073629769Q50533832-F32A6F4F-04D9-430A-ACC5-0BB6714D5C23Q50617047-E7F151F5-EEF2-4E6C-BF8B-AB4ADD1C5E54Q50657296-4737797E-482F-489F-89E2-44984F013157Q50661326-C816F34E-FA0E-4A06-BB2F-189D29E0607CQ51826207-9A5E4E4F-C799-4C19-9659-2F5B4C2CDCB9Q51861390-78FBDA4D-975B-41AB-ADDA-98338D848329Q55041866-64F6851B-A9CD-4669-8E8F-3353C3EC7854Q55362920-35360F64-974D-4177-A601-90B7A001639CQ60198553-56E49DF6-4D56-46F0-8595-3601DFC0F9A5Q60198554-8C0A1AA7-40DF-4FC4-B9C9-2231D3B893FC
P50
description
Dutch psychiatrist
@en
Nederlands psychiater
@nl
hollandsk psykiater
@da
psiquiatra neerlandés
@es
طبيب نفسي هولندي
@ar
name
Lex Wunderink
@ast
Lex Wunderink
@ca
Lex Wunderink
@da
Lex Wunderink
@de
Lex Wunderink
@en
Lex Wunderink
@es
Lex Wunderink
@fo
Lex Wunderink
@fr
Lex Wunderink
@id
Lex Wunderink
@is
type
label
Lex Wunderink
@ast
Lex Wunderink
@ca
Lex Wunderink
@da
Lex Wunderink
@de
Lex Wunderink
@en
Lex Wunderink
@es
Lex Wunderink
@fo
Lex Wunderink
@fr
Lex Wunderink
@id
Lex Wunderink
@is
altLabel
L. Wunderink
@nl
prefLabel
Lex Wunderink
@ast
Lex Wunderink
@ca
Lex Wunderink
@da
Lex Wunderink
@de
Lex Wunderink
@en
Lex Wunderink
@es
Lex Wunderink
@fo
Lex Wunderink
@fr
Lex Wunderink
@id
Lex Wunderink
@is
P1006
P214
P1006
P1153
16403805600
P21
P213
0000 0003 9147 8669
P214
P31
P496
0000-0002-4150-4681
P569
1954-01-01T00:00:00Z
2000-01-01T00:00:00Z
P735
P7859
viaf-285363856